 | • レポートコード：MRC2203A361 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のC反応性蛋白（CRP）検査市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、アッセイ種類別（酵素免疫測定法（ELISA）、化学発光イムノアッセイ（CLIA）、免疫比濁アッセイ、その他）分析、用途別（糖尿病、関節リウマチ、心血管疾患、炎症性腸疾患、がん）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のC反応性蛋白（CRP）検査市場規模：アッセイ種類別（酵素免疫測定法（ELISA）、化学発光イムノアッセイ（CLIA）、免疫比濁アッセイ、その他） ・世界のC反応性蛋白（CRP）検査市場規模：用途別（糖尿病、関節リウマチ、心血管疾患、炎症性腸疾患、がん） ・世界のC反応性蛋白（CRP）検査市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abaxis Inc. (Zoetis)、Abbott Laboratories、Beckman Coulter Inc. (Danaher Corporation)、…） ・市場機会・将来傾向 |
The C-reactive Protein Testing Market is expected to register a CAGR of 2.2% during the forecast period. The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, the increasing global incidence of endometriosis in women, rise in funding toward the technological advancement in diagnostics, and rise in the adoption of point-of-care devices.
Chronic inflammation is found to be the primary contributing factor involved in multiple chronic diseases, such as rheumatoid arthritis, lupus, ulcerative colitis, Crohn’s disease, and others. According to the Centers for Disease Control and Prevention (CDC) 2016 report, estimates that by 2040, an estimated about 78 million (26%) United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis.
During the infectious state of the inflammatory disease, the CRP levels rise rapidly within the body and peak up to levels of 350–400 mg/L after 48 hours. When the inflammation decreases, the CRP levels fall, making it a highly useful marker for monitoring the activity of diseases. Therefore, a regular standardization of measurement techniques and reporting improve the utility of CRP in regular clinical practice. CRP has multiple applications within in vitro and in vivo, for the development of potential new compounds for inflammatory diseases. Thus, the rising prevalence of inflammatory diseases is among the foremost factors driving the market studied.
Furthermore, there is also an increase in funds provided to academic research institutions and individual researchers that is expected to boost the market growth. Moreover, various initiatives by international bodies, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular diseases and cancer are anticipated to promote the growth of the market.
Key Market Trends
Cardiovascular Disease is the Largest Segment Under Application that is Expected to Grow in the Forecast Period
Cardiovascular disorders account for the largest share in terms of adoption. Due to the high prevalence of cardiovascular diseases, there is an urgent need for developing a quick and effective method for diagnosis. So, C-reactive protein can be an indicator for the detection of CVD as there is a development of atherosclerosis, which is the laying down of cholesterol inside the blood vessel walls that create inflammation within the vessel walls. Hence, in patients suffering from CVD, there is a higher level of CRP.
Therefore, the CRP assays to detect lower levels of CRP, which are sensitive. Hence, the high incidence rate of cardiovascular diseases is expected to encourage researchers to undertake investigational studies in CRC for cardiovascular disorders. According to the World Heart Federation, coronary heart disease is the leading cause of death worldwide. An estimated 3.8 million men and 3.4 million women die each year from coronary heart disease. In addition, 80% of the deaths occur in low- and middle-income countries. Hence owing to above all factors the cardiovascular disease segment is expected to show significant growth over the forecast period.
North America has Been Reported with the Largest Growth and is Expected to Follow the Same Trend Over the Forecast Period
North America has dominated the market with the largest revenue share. The factors that are likely to be responsible for the dominance of this segment are the presence of established players, technological advancements, and well-established healthcare infrastructure.
According to the Centers for Disease Control and Prevention, in the year 2017, coronary heart disease is the most common type of heart disease, killing approximately 365,914 people in the United States. Moreover, about 18.2 million adults age 20 and older have Coronary heart disease (CAD), 2 in 10 deaths from Coronary heart disease happen in adults less than 65 years old. Furthermore, due to effective government policies, a huge base of multinational companies, as well as high awareness among the people for testing and testing devices in healthcare, the market is expected to grow in the upcoming years.
Competitive Landscape
The C-reactive Protein Testing Market is fragmented competitive. Some of the major players are seen forming strategic partnerships with other market players to expand their product portfolios. They are also looking to expand their R&D, distribution, and management facilities to gain a competitive edge in the market. Some of the companies which are currently dominating the market are Abaxis Inc (Zoetis), Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings, Merck KGaA, Quest Diagnostics, Randox Laboratories Ltd, Siemens Healthineers and Thermo Fisher Scientific Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Inflammatory Disorders
4.2.2 Increasing Global Incidence of Endometriosis in Women
4.2.3 Rise in Funding toward the Technological Advancement in Diagnostics
4.2.4 Rise in the Adoption of Point-of-care Devices
4.3 Market Restraints
4.3.1 Lack of Public Awareness
4.3.2 Availability of Alternative Treatments with Higher Accuracies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Assay Type
5.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
5.1.2 Chemiluminescence Immunoassay (CLIA)
5.1.3 Immunoturbidimetric Assay
5.1.4 Other Assay Types
5.2 By Application
5.2.1 Diabetes
5.2.2 Rheumatoid Arthritis
5.2.3 Cardiovascular Disease
5.2.4 Inflammatory Bowel Disease
5.2.5 Cancer
5.2.6 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abaxis Inc. (Zoetis)
6.1.2 Abbott Laboratories
6.1.3 Beckman Coulter Inc. (Danaher Corporation)
6.1.4 F. Hoffmann-La Roche AG
6.1.5 Laboratory Corporation of America Holdings
6.1.6 Merck KGaA
6.1.7 Quest Diagnostics
6.1.8 Randox Laboratories Ltd
6.1.9 Siemens Healthineers
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS